Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Immune Response and Safety of RSVPreF3 OA Vaccine in Adults Aged 60+ with Respiratory Syncytial Virus Infections

Fast replyRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a disease called Respiratory Syncytial Virus (RSV) infections, which can cause respiratory illnesses, especially in older adults. The study will use a vaccine known as Arexvy, which is designed to help the body build protection against RSV. This vaccine is given as an injection and contains a special protein from the virus, combined with an ingredient that helps boost the body's immune response.

The purpose of the study is to evaluate how well the vaccine works and how safe it is for people aged 60 and above. Participants in the study will receive the vaccine at different times to see how their immune systems respond. Some participants will receive a single dose of the vaccine, while others will receive a revaccination dose before the RSV season. The study will monitor the immune response by measuring the levels of protective substances in the blood before and after vaccination.

Throughout the study, participants will be observed for any side effects or health changes. The study will also track any serious health events that occur after vaccination. This research aims to understand the best vaccination schedule to protect older adults from RSV infections effectively.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, participants will be required to provide written or witnessed informed consent. This is a formal agreement to participate in the study after understanding all the procedures involved.

    Participants must have been part of the previous RSV OA=ADJ-006 study and either received a placebo or a single dose of the RSVPreF3 OA vaccine.

  2. Step 2

    Initial assessment

    Participants will undergo an initial assessment to ensure they are medically stable. This includes checking for chronic stable medical conditions such as diabetes, hypertension, or cardiac disease.

    The investigator will determine if participants can comply with the study requirements, such as completing diary cards and attending regular phone calls or study site visits.

  3. Step 3

    Vaccination

    Participants will receive a single dose of the RSVPreF3 OA vaccine, which is a vaccine against respiratory syncytial virus. The vaccine is administered as a suspension for injection through intramuscular use.

    The timing of the vaccination depends on the group assignment: either before Season 4 or before Season 5.

  4. Step 4

    Follow-up period

    After vaccination, participants will be monitored for a 30-day follow-up period. During this time, any unsolicited adverse events (AEs) will be recorded.

    Participants will also be monitored for serious adverse events (SAEs) and potential immune-mediated diseases (pIMDs) from the day of vaccination up to six months after vaccination.

  5. Step 5

    Immunogenicity assessment

    The study will evaluate the immune response by measuring RSV-A and RSV-B neutralizing titers before and after vaccination. This involves checking the levels of antibodies that can neutralize the virus.

    For the RSV_PreS4 group, this assessment occurs before revaccination and 30 days post-revaccination. For the RSV_PreS5 group, it includes additional assessments at pre-Season 5 and pre-Season 6.

  6. Step 6

    Study completion

    The study is estimated to end by September 30, 2026. Participants will continue to be monitored for any SAEs or pIMDs related to the study vaccination until the study concludes.

    Participants will be informed of the study results and any relevant findings related to their health.

Who can join the trial?

4 criteria

  • Participants must be male or female who were previously part of the RSV OA=ADJ-006 study and received either a placebo (a harmless pill or injection with no active medicine) or a single dose of the RSVPreF3 OA vaccine.
  • Participants should be able to follow the study requirements, such as filling out diary cards, attending regular phone calls or study site visits, and using a phone or other electronic communication devices. If a participant cannot fill out the diary cards due to physical limitations, they can have help from site staff or a caregiver, but these helpers cannot make health decisions for the participant.
  • Participants must provide written or witnessed informed consent before any study-specific procedures are performed. This means they agree to participate after understanding the study details.
  • Participants should be medically stable at the start of the study, as judged by the investigator. This means their health condition is not changing rapidly. Participants with ongoing stable medical conditions, like diabetes, high blood pressure, or heart disease, can join the study.

Who cannot join the trial?

8 criteria

  • Patients who have a known allergy to any component of the vaccine cannot participate.
  • Individuals with a history of severe allergic reactions, also known as anaphylaxis, to any vaccine are excluded. Anaphylaxis is a serious and rapid allergic reaction that can be life-threatening.
  • Participants who have received any other vaccine within 30 days prior to the study start date are not eligible.
  • People with a weakened immune system, which means their body has a reduced ability to fight infections, cannot take part in the study.
  • Individuals currently participating in another clinical trial are not allowed to join this study.
  • Pregnant or breastfeeding women are excluded from participating in the trial.
  • Anyone with a current or recent respiratory illness, which affects the lungs and breathing, is not eligible.
  • Participants with any condition that, in the opinion of the study doctor, might interfere with the results of the study or the safety of the participant are excluded.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

RSVPreF3 OA vaccine is a vaccine designed to protect against respiratory syncytial virus (RSV) in older adults. This vaccine works by stimulating the body's immune system to produce antibodies that can fight off the virus if the person is exposed to it in the future. In this clinical trial, the vaccine is being tested to see how well it works when given as a single revaccination dose before the RSV season, and to check how long the protection lasts in adults aged 60 years and above.

What is already known about the treatment

RSVPreF3 OA vaccine – This vaccine is administered as an injection to help protect against Respiratory Syncytial Virus (RSV) infections, particularly in adults aged 60 years and older. Currently, it is being studied in clinical trials to assess its effectiveness and safety when given as a single revaccination dose before the RSV season. The vaccine works by stimulating the body's immune system to produce antibodies that target the RSV virus, helping to prevent infection. It is classified as a vaccine, which is a type of medication designed to boost the immune system's ability to fight off specific infections.

Investigated diseases

Respiratory Syncytial Virus Infections – Respiratory Syncytial Virus (RSV) infections are caused by a virus that primarily affects the respiratory tract. The virus is highly contagious and spreads through droplets from coughs or sneezes. Infections often begin with symptoms similar to a common cold, such as a runny nose, cough, and fever. As the infection progresses, it can lead to more severe respiratory issues, especially in infants and older adults, such as bronchiolitis or pneumonia. The virus can cause inflammation and obstruction of the small airways in the lungs, leading to difficulty breathing. Recovery from the infection can take several weeks, with symptoms gradually improving over time.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2023-509762-38-00Protocol code222090Estimated enrolment12 300 patientsSponsorGlaxoSmithKline Biologicals

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.